Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
NEW YORK, Dec. 02, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Diplomat Pharmacy, Inc. (“Diplomat Pharmacy”) (NYSE:DPLO) between October 9, 2014 and November 2, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of Michigan. To get more information go to:
http://www.zlk.com/pslra/diplomat-pharmacy
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Diplomat Pharmacy issued false and misleading statements to investors and/or failed to disclose that: (1) the Company lacked adequate internal controls over its financial reporting and thus could not adequately calculate DIR fees; (2) Diplomat Pharmacy’s hepatitis C segment was not performing as previously disclosed to investors; (3) the Company overstated its full-year 2016 guidance; and (4) as a result of the above, Diplomat Pharmacy’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
On November 2, 2016, Diplomat Pharmacy announced third quarter 2016 results that were below investors’ expectations and lowered its full year 2016 guidance. When this news was announced, shares of Diplomat Pharmacy fell in value, causing investors harm.
If you suffered a loss in Diplomat Pharmacy you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
